Obicetrapib Clinical Trials (2026): 18 Studies for High Cholesterol & Hypercholesterolemia

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

18 Obicetrapib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including High Cholesterol & Hypercholesterolemia) and 14,305 total planned enrollment. 6 Phase 3 Obicetrapib trials and 7 Phase 2 are listed. 3 Obicetrapib clinical trials are actively recruiting at 22 U.S. sites across 14 states. Most recent activity: NCT07219602 (Jun 2028).

Where to Participate: All Obicetrapib Trial Sites in the U.S. (22 sites across 14 states)

Every actively recruiting Obicetrapibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
AZClinical Research Institute of ArizonaSun City West85375NCT07219602Map
CAScripps Health - Whittier Diabetes InstituteLa Jolla92037NCT07219602Map
FLEast Coast Institute of Research LLCJacksonville32216NCT07219602Map
FLUF Health JacksonJacksonville32209NCT07219602Map
FLEast Coast Institute of Research LLCLake City32055NCT07219602Map
FLExcellence Medical ResearchMiami Gardens33169NCT06982508Map
FLFloridian Clinical ResearchMiami Lakes33016NCT07219602Map
KYLouisville Metabolic and Atherosclerosis Research Center (L-MARC)Louisville40213NCT07219602Map
MDMD Medical ResearchOxon Hill20745NCT07219602Map
MOJefferson City Medical GroupJefferson City65109NCT07219602Map
MTMontana Medical ResearchMissoula59808NCT07219602Map
NJInspira Health - Internal Medicine AssociatesBridgeton08302NCT07219602Map
NYCentral New York Clinical ResearchManlius13104NCT07219602Map
NCVelocity Clinical ResearchDurham27710NCT07219602Map
NCFloridian Clinical ResearchGreensboro27408NCT07219602Map
NCCentricity Research dba Lucas ResearchMorehead City28557NCT07219602Map
OHSummit Research GroupMunroe Falls44262NCT07219602Map
PAUPennPhiladelphia19104NCT06496243Map
TXJuno Research LLC - Medical CenterHouston77054NCT07219602Map
TXClinical Trials of Texas dba Flourish ResearchSan Antonio78229NCT07219602Map
VABurke Internal MedicineBurke22015-2234NCT07219602Map
VABurke International Medicine DBA Manassas Clinical Research CenterManassas20110NCT07219602Map

Obicetrapib clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingcompletedTotal
P1145
P2257
P31236

Recruiting Obicetrapib clinical trials (3)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07219602RUBENSA Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromeP3Lipidemia300Dec 2025
NCT06496243VINCENTImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) LevelsP2Dyslipidemias69Dec 2024
NCT06982508VERMEEREvaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy VolunteersP2Antioxidant Absorption100Sep 2025

Obicetrapib clinical trials by indication

Dyslipidemias (7)

NCTAcronymPhaseStatusTitle
NCT06496243VINCENTP2recruitingImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
NCT06005597TANDEMP3completedStudy of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT05142722BROADWAYP3completedRandomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT05425745BROOKLYNP3completedEvaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
NCT05266586ROSE2P2completedStudy to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
NCT04753606ROSEP2completedRandomized Study of Obicetrapib as an Adjunct to Statin Therapy
NCT04770389OCEANP2completedRandomized Study of Obicetrapib in Combination With Ezetimibe

Healthy Volunteers (3)

NCTAcronymPhaseStatusTitle
NCT06547359P1completedA Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects
NCT06250205COCP1completedEvaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
NCT06081166P1completedA Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

Lipidemia (2)

NCTAcronymPhaseStatusTitle
NCT07219602RUBENSP3recruitingA Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT06305559REMBRANDTP3active not recruitingA CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

Antioxidant Absorption (1)

NCTAcronymPhaseStatusTitle
NCT06982508VERMEERP2recruitingEvaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

Lipid Metabolism (1)

NCTAcronymPhaseStatusTitle
NCT05972278P1active not recruitingInvestigating the Effect of Obicetrapib on Lipoprotein Metabolism

Hepatic Impairment (1)

NCTAcronymPhaseStatusTitle
NCT06048302P1completedPK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

Dyslipidemia (1)

NCTAcronymPhaseStatusTitle
NCT05421078P2completedA Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

Atherosclerotic Cardiovascular Disease (1)

NCTAcronymPhaseStatusTitle
NCT05202509PREVAILP3active not recruitingCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Early Alzheimer's Disease (1)

NCTAcronymPhaseStatusTitle
NCT05161715P2completedProof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

Obicetrapib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
RUBENSNCT07219602P3recruitingLipidemia300
REMBRANDTNCT06305559P3active not recruitingLipidemia300
PREVAILNCT05202509P3active not recruitingAtherosclerotic Cardiovascular Disease9,541
TANDEMNCT06005597P3completedDyslipidemias407
BROADWAYNCT05142722P3completedDyslipidemias2,530
BROOKLYNNCT05425745P3completedDyslipidemias354
VINCENTNCT06496243P2recruitingDyslipidemias69
VERMEERNCT06982508P2recruitingAntioxidant Absorption100
ROSE2NCT05266586P2completedDyslipidemias119
ROSENCT04753606P2completedDyslipidemias120
OCEANNCT04770389P2completedDyslipidemias112

All Obicetrapib trials (18)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07219602RUBENSA Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromeP3recruiting300NewAmsterdam PharmaDec 2025
NCT06305559REMBRANDTA CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaqueP3active not recruiting300NewAmsterdam PharmaMay 2024
NCT06496243VINCENTImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) LevelsP2recruiting69NewAmsterdam PharmaDec 2024
NCT06982508VERMEEREvaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy VolunteersP2recruiting100NewAmsterdam PharmaSep 2025
NCT05202509PREVAILCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseaseP3active not recruiting9,541NewAmsterdam PharmaFeb 2022
NCT06547359A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult SubjectsP1completed94NewAmsterdam PharmaOct 2024
NCT06005597TANDEMStudy of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying TherapiesP3completed407NewAmsterdam PharmaMar 2024
NCT05972278Investigating the Effect of Obicetrapib on Lipoprotein MetabolismP1active not recruiting22NewAmsterdam PharmaDec 2023
NCT05142722BROADWAYRandomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesP3completed2,530NewAmsterdam PharmaDec 2021
NCT05425745BROOKLYNEvaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.P3completed354NewAmsterdam PharmaJul 2022
NCT06250205COCEvaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without ObicetrapibP1completed30NewAmsterdam PharmaFeb 2024
NCT06048302PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic FunctionP1completed18NewAmsterdam PharmaNov 2023
NCT06081166A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and RosuvastatinP1completed74NewAmsterdam PharmaNov 2023
NCT05161715Proof-of-concept, Open-label Study in Patients With Early Alzheimer's DiseaseP2completed13NewAmsterdam PharmaJan 2022
NCT05421078A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.P2completed102NewAmsterdam PharmaJun 2022
NCT05266586ROSE2Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS TherapyP2completed119NewAmsterdam PharmaMar 2022
NCT04753606ROSERandomized Study of Obicetrapib as an Adjunct to Statin TherapyP2completed120NewAmsterdam PharmaFeb 2021
NCT04770389OCEANRandomized Study of Obicetrapib in Combination With EzetimibeP2completed112NewAmsterdam PharmaFeb 2021

Obicetrapib clinical trials: frequently asked questions

How many Obicetrapib clinical trials are there?
18 Obicetrapib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 12 are marked completed.
Are Obicetrapib clinical trials recruiting in 2026?
Yes — 3 Obicetrapib trials are actively recruiting in 2026, with 22 U.S. sites across 14 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Obicetrapib being studied for?
Obicetrapib is being studied for High Cholesterol, Hypercholesterolemia, Dyslipidemias, Healthy Volunteers, Familial Hypercholesterolemia and 18 more. The trials are grouped by indication on this page.
What phase is Obicetrapib in?
Obicetrapib clinical trials span 6 Phase 3, 7 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Obicetrapib clinical trials?
The lead sponsor across the most Obicetrapib trials is NewAmsterdam Pharma. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Obicetrapibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: